The correlation of high CEBPB expression with unfavorable outcomes, along with the observed DUSP1 downregulation in CRC, highlights the potential of this regulatory axis as both a diagnostic and therapeutic target [26]. This evidence concerns the gene DUSP1 and colorectal carcinoma.